January 08, 2019

Pisano to Present on TMIST at ACR-RBMA Practice Leaders Forum

At the 2019 ACR-RBMA Practice Leaders Forum, Tomosynthesis Mammographic Imaging Screening Trial (TMIST) principal investigator Etta Pisano, MD, will show attendees how TMIST participation can strengthen your practice, expand access to the latest care in your community (and to the uninsured) and shape breast cancer screening policy.

Pisano will speak during the plenary session Saturday, Jan. 12 at 1pm Central Time. She will host a dinner that night at the host hotel for those who may be interested in taking part in TMIST.

In both events, she will highlight the new acr.org/TMIST website.

TMIST Ramping Up

Nearly 50 sites are now open and accruing patients. The trial will add 80 more sites in North America and enroll 165,000 healthy women, ages 45 to 74, who are already planning to get routine mammograms.

TMIST is the first large randomized, controlled trial (RCT) that would identify women in which digital breast tomosynthesis (DBT) may outpace (2D) digital mammography at reducing advanced breast cancer development.

Strengthen Your Practice

TMIST sites Receive $500 for data submission for each insured and uninsured patient enrolled (includes payment for first screening exam).

Sites are also paid $150 for each subsequent screening exam for participants with private insurance, Medicare or Medicaid — in addition to insurance payment.

Expand Screening Access to the Underserved in Your Area

TMIST sites receive $288 per screening exam ($138.17 for performing exam + $150 for data submission for exam) for uninsured participants who qualify for charity care at your site.

This rare payment empowers your practice to offer the latest care to the underserved and expand minority participation in clinical trials.

Move Breast Cancer Screening Forward

The study provides additional payment to sites for submission of biopsy, blood and buccal smear samples that patients are asked to provide.

These submissions will create the world’s largest breast cancer screening biorepository to help tailor future, risk-based screening policy.

TMIST is necessary to inform tomosynthesis clinical and payment updates. Decision makers rarely update clinical or payment policy without such a large RCT in the evidence base.

Visit acr.org/TMIST to get more information on how your practice can become a TMIST site.

Email TMIST@acr.org with any questions you may have about TMIST.